News
CLNNW
0.0900
-10.00%
-0.0100
BRIEF-Clene Reports Full Year 2022 Financial Results
Reuters · 03/13 11:36
BRIEF-Cnm-Au8 Associated With Delayed Time To Key Clinical Progression Events At Six Months In Als Platform Trial
Reuters · 03/09 12:27
BRIEF-Clene Inc Enters Purchase Agreement With Lincoln Park Capital Fund LLC
Reuters · 03/03 22:21
BRIEF-David Matlin Reports 7.6% Stake In Clene Inc
Reuters · 02/06 17:49
BRIEF-Clene Reports Topline Results Of Phase 2 Covid-19 Study Of CNM-ZnAg
Reuters · 12/27/2022 21:55
BRIEF-Clene Enters Into Amendment No. 1 To Equity Distribution Agreement
Reuters · 12/20/2022 11:23
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating disease modifying therapi...
GlobeNewswire · 11/28/2022 13:00
BRIEF-Clene Reports Third Quarter 2022 Financial Results And Recent Operating Highlights
Reuters · 11/07/2022 13:59
BRIEF-Clene Announces $10.8 Million Registered Direct Offering And $5 Million Debt Facility From The State Of Maryland
Reuters · 10/31/2022 12:14
BRIEF-Clene Reports Topline Results Demonstrating Survival Signal For CNM-AU8® In Healey Als Platform Trial
BRIEF-Clene Reports Topline Results Demonstrating Survival Signal For CNM-AU8® In Healey Als Platform Trial
Reuters · 10/03/2022 12:36
BRIEF-Clene Nanomedicine Presents Updated Long-Term Survival Data From Rescue-ALS Participants
BRIEF-Clene Nanomedicine Presents Updated Long-Term Survival Data From Rescue-ALS Participants
Reuters · 09/21/2022 11:33
Clene to Present at Upcoming September Investor Conferences
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of...
GlobeNewswire · 08/30/2022 11:00
BRIEF-Clene Reports Positive Topline Results For Cnm-Au8 In The Phase 2 Visionary-MS Trial In Multiple Sclerosis
BRIEF-Clene Reports Positive Topline Results For Cnm-Au8 In The Phase 2 Visionary-MS Trial In Multiple Sclerosis
Reuters · 08/15/2022 11:46
BRIEF-Clene Reports Q2 2022 Financial Results
BRIEF-Clene Reports Q2 2022 Financial Results
Reuters · 08/15/2022 11:13
Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights
Topline results from the Phase 2 VISIONARY-MS clinical trial with CNM-Au8® met the primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mI...
GlobeNewswire · 08/15/2022 11:00
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT populationConsistent improvements favoring CNM-Au8 were seen across ...
GlobeNewswire · 08/15/2022 11:00
Clene to Host VISIONARY-MS Results Call and Webcast on August 15
SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of...
GlobeNewswire · 08/12/2022 20:01
BRIEF-Clene Inc - Received Positive Opinion For Submission Requesting Orphan Drug Designation For Cnm-Au8 For Treatment Of Als From EMA Comp
BRIEF-Clene Inc - Received Positive Opinion For Submission Requesting Orphan Drug Designation For Cnm-Au8 For Treatment Of Als From EMA Comp
Reuters · 07/19/2022 11:15
Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS
SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment ...
GlobeNewswire · 07/19/2022 11:00
Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths vs. 14 placebo deaths, HR=0.301, p=0.0143)CNM-Au8 treatment was well-tolerated, and there were no significant safety findings reporte...
GlobeNewswire · 07/14/2022 11:00
More
Webull provides a variety of real-time CLNNW stock news. You can receive the latest news about Clene through multiple platforms. This information may help you make smarter investment decisions.
About CLNNW
Clene Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure and neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is being evaluated in a Phase III registration trial in amyotrophic lateral sclerosis (ALS) and a Phase II trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). The Company has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.